# Chronic Obstructive Pulmonary Disease

COPD requires confirmation with post-bronchodilator spirometry, then treatment guided by symptoms, exacerbation history, inhaler delivery, eosinophils, and comorbidity rather than FEV₁ alone. Long-acting bronchodilation is foundational; escalation should target the dominant residual problem while minimizing avoidable inhaled corticosteroid and treatment toxicity.

**Clinical question:** How should clinicians confirm COPD, stratify current risk, and select maintenance therapy while reducing exacerbations and treatment harms?

Updated: 2026-08-20T23:30:14.514374Z

## What matters in practice
- Confirm COPD with post-bronchodilator FEV₁/FVC <0.70; symptom burden and exacerbation history determine the GOLD ABE clinical group, whereas FEV₁ percent predicted grades airflow limitation. [12][13]
- Use CAT preferentially when feasible; CAT ≥10 or mMRC ≥2 denotes higher symptom burden. Group E comprises ≥2 moderate exacerbations/year or ≥1 hospitalization, irrespective of symptom burden. [12][13]
- For persistent symptoms or exacerbations, first verify inhaler technique, adherence, diagnosis, ongoing exposures, and alternative causes of dyspnea before escalating treatment. Spirometry errors and diagnostic alternatives are common contributors to COPD misclassification. [19]
- Long-acting bronchodilator therapy is the core maintenance approach. Tiotropium 5 mcg once daily reduces COPD exacerbations and is not rescue treatment. [5]
- Blood eosinophils inform the expected preventive benefit of ICS: little or no effect is reported below 100 cells/µL and maximal effect at or above 300 cells/µL; balance this against pneumonia risk in COPD. [12][2]
- Consider roflumilast only for its labeled phenotype: severe COPD associated with chronic bronchitis and prior exacerbations; monitor weight and psychiatric symptoms. [3]

## Confirm persistent airflow obstruction and define the treatment phenotype

Clinical labels without quality spirometry are insufficient for long-term pharmacologic decisions.

Obtain spirometry after an adequate dose of at least one short-acting inhaled bronchodilator. A post-bronchodilator FEV₁/FVC ratio <0.70 supports COPD; complete absence of bronchodilator reversibility is neither necessary nor typical. Grade obstruction by post-bronchodilator FEV₁: GOLD 1, ≥80% predicted; GOLD 2, 50% to <80%; GOLD 3, 30% to <50%; and GOLD 4, <30%. [12][13]

Separate physiologic severity from current clinical risk. Record CAT or mMRC, prior-year treated exacerbations and hospitalizations, smoking status and other inhalational exposures, resting and exertional oxygenation when clinically indicated, BMI or weight trajectory, comorbidity burden, and the current inhaler regimen including actual use. GOLD ABE assigns Group A to low symptoms with 0–1 nonhospitalized exacerbation, Group B to higher symptoms with 0–1 nonhospitalized exacerbation, and Group E to ≥2 exacerbations or ≥1 hospitalization regardless of symptoms. [12][13]

Misdiagnosis is clinically consequential because diagnostic errors often arise from spirometry technique or interpretation, primary-care assessment, diagnostic thresholds, and alternative diagnoses. Reassess patients with discordant symptom burden, imaging, exposure history, or spirometry before indefinitely intensifying COPD medications. [19]
- Use chest radiography primarily to evaluate alternative disease or complications; hyperinflation may be present but is not diagnostic. [12]
- Obtain arterial blood gas testing in acute illness with abnormal oximetry and in stable disease with FEV₁ <35% predicted, signs of respiratory failure, or SpO₂ ≤92%; PaCO₂ >50 mm Hg and/or PaO₂ <60 mm Hg suggests respiratory insufficiency. [12]
- Consider full pulmonary function testing and DLCO for disproportionate dyspnea or diagnostic uncertainty; DLCO <60% predicted is associated with reduced exercise capacity, worse health status, and increased mortality. [12]
- Consider chest CT for persistent exacerbations, symptoms disproportionate to lung-function impairment, FEV₁ <45% predicted with substantial hyperinflation, or lung cancer screening eligibility. [12]
- Screen once for alpha-1 antitrypsin deficiency in confirmed COPD, particularly in younger patients, nonsmokers, atypical emphysema, or positive family history. [12]

*COPD assessment elements that directly change management. [12][13]*

| Domain | Actionable finding | Clinical implication |
| --- | --- | --- |
| Spirometry | Post-bronchodilator FEV₁/FVC <0.70 [12][13] | Confirms persistent airflow obstruction compatible with COPD. |
| Symptoms | CAT ≥10 or mMRC ≥2 [12][13] | Higher symptom burden; assess activity limitation, inhaler adequacy, and competing causes of dyspnea. |
| Exacerbations | ≥2 treated exacerbations/year or ≥1 hospitalization [13] | Group E; prioritize exacerbation prevention and assess preventive therapy selection. |
| Blood eosinophils | <100 versus ≥300 cells/µL [12] | Lower versus greatest expected preventive benefit from adding ICS to long-acting bronchodilator therapy. |
| Oxygenation | SpO₂ ≤92% [12] | Obtain ABG when clinically appropriate and evaluate respiratory failure. |

## Select maintenance therapy by residual symptoms, exacerbations, and delivery feasibility

The supplied evidence supports specific labeled agents and safety constraints, not a universal drug sequence.

Long-acting bronchodilation is central to maintenance treatment. Tiotropium, a long-acting muscarinic antagonist (LAMA), is labeled for once-daily COPD maintenance and exacerbation reduction at two 2.5-mcg inhalations once daily (total 5 mcg). It is not a rescue medication; treat acute bronchospasm with a rapid-acting beta₂-agonist. In placebo-controlled trials, tiotropium reduced exacerbation rates and delayed time to first exacerbation. [5]

Before changing medication, directly observe device use and determine whether the prescribed device matches inspiratory capacity, dexterity, cognition, visual function, and cost/access. Persistent symptoms may reflect incorrect delivery, undertreatment, deconditioning, cardiac disease, anemia, obesity, sleep-disordered breathing, pulmonary vascular disease, or another diagnosis rather than insufficient bronchodilation. [12][19]

ICS-containing therapy is an exacerbation-prevention strategy, not a substitute for bronchodilator optimization. Blood eosinophils estimate the likelihood of benefit: evidence summarized in GOLD indicates little or no ICS effect below 100 cells/µL and maximal effect at ≥300 cells/µL. In COPD, ICS-containing fluticasone furoate/vilanterol increased pneumonia incidence versus vilanterol alone in replicate 12-month trials (6% with 100/25 mcg vs 3% with vilanterol); monitor for pneumonia because clinical features overlap with exacerbation. [12][2]
- Breo Ellipta (fluticasone furoate/vilanterol) is labeled for COPD maintenance at 100/25 mcg, one inhalation once daily; it is not indicated for acute bronchospasm. Rinse mouth after use to reduce candidiasis risk. [2]
- Avoid concurrent LABA-containing products. With fluticasone furoate/vilanterol, use caution with strong CYP3A4 inhibitors because systemic corticosteroid and cardiovascular effects may increase. [2]
- For tiotropium, avoid other anticholinergic-containing drugs when possible; use caution with narrow-angle glaucoma, urinary retention, prostatic hyperplasia, bladder-neck obstruction, and moderate-to-severe renal impairment. [5]
- Nebulized formoterol is labeled for COPD maintenance at 20 mcg/2 mL twice daily; do not use for acute deterioration, do not exceed 40 mcg/day, and do not combine with another LABA. [8]
- Roflumilast is labeled at 500 mcg orally once daily to reduce exacerbation risk in severe COPD associated with chronic bronchitis and prior exacerbations. It is not a bronchodilator or rescue treatment. [3]

### When to consider roflumilast

Roflumilast is a selective PDE4 inhibitor with a labeled role in the chronic-bronchitis, severe-COPD, prior-exacerbation phenotype. In two supporting 1-year trials, roflumilast reduced moderate or severe exacerbation rates by 15% and 18% versus placebo; mean FEV₁ treatment effects were approximately 39 to 58 mL in those trials. [3]
- Avoid in moderate or severe hepatic impairment (Child-Pugh B or C); weigh risks and benefits in mild impairment. [3]
- Monitor weight regularly. In one-year trials, 20% had 5%–10% weight loss and 7% had >10% weight loss, versus 7% and 2% with placebo. [3]
- Assess depression, anxiety, insomnia, and suicidal ideation before and during treatment. Psychiatric adverse reactions occurred in 5.9% with roflumilast versus 3.3% with placebo in controlled trials. [3]
- Avoid strong CYP inducers such as rifampin, phenobarbital, carbamazepine, and phenytoin; CYP3A4 or combined CYP3A4/CYP1A2 inhibitors can increase exposure and adverse effects. [3]

*Selected U.S.-labeled maintenance options represented in the supplied sources. [2][3][5][8]*

| Agent | Labeled COPD dose | Best-supported role and key precautions |
| --- | --- | --- |
| Tiotropium Respimat | 2 inhalations of 2.5 mcg once daily; total 5 mcg/day [5] | LAMA maintenance therapy and exacerbation reduction; not rescue. Monitor anticholinergic effects in renal impairment; caution with glaucoma and urinary retention. |
| Fluticasone furoate/vilanterol | 100/25 mcg, 1 inhalation once daily [2] | ICS/LABA maintenance option; not rescue. Rinse mouth; monitor for candidiasis and pneumonia; do not add another LABA. |
| Formoterol nebulized | 20 mcg/2 mL via standard jet nebulizer twice daily; maximum 40 mcg/day [8] | LABA maintenance option for patients using nebulized delivery; not rescue and not with another LABA. |
| Roflumilast | 500 mcg orally once daily [3] | Exacerbation reduction in severe COPD with chronic bronchitis and prior exacerbations; monitor weight and psychiatric effects; contraindicated in Child-Pugh B/C. |

## Use ensifentrine as an add-on maintenance option when nebulized delivery is appropriate

Ensifentrine offers bronchodilator and anti-inflammatory enzyme inhibition but does not replace rescue therapy.

Ensifentrine is an inhaled dual PDE3/PDE4 inhibitor labeled for maintenance treatment of COPD in adults. The labeled dose is 3 mg by standard jet nebulizer with mouthpiece twice daily, using one unit-dose ampule each morning and evening; do not physically mix it with other nebulized medications because compatibility has not been established. [4]

In ENHANCE-1 and ENHANCE-2, ensifentrine improved Week-12 FEV₁ AUC₀–12h versus placebo by 87 mL and 94 mL, respectively. The trials enrolled patients with moderate-to-severe COPD, and many received concurrent LAMA, LABA, or LABA/ICS therapy; therefore, the evidence supports use alongside existing maintenance bronchodilator regimens in selected patients rather than as an acute bronchodilator. [4]
- Do not use ensifentrine for acute bronchospasm; use an inhaled short-acting bronchodilator for acute symptoms. [4]
- Discontinue if paradoxical bronchospasm occurs. [4]
- Assess psychiatric history and reassess mood changes, insomnia, anxiety, depression, or suicidality during therapy. [4]
- Use caution in hepatic impairment; systemic exposure was approximately 2.3-fold higher with moderate or severe hepatic impairment. [4]

## Treat modifiable risk, functional decline, and preventable complications

Maintenance pharmacotherapy is only one component of COPD outcome modification.

Smoking cessation remains the central exposure-targeted intervention. At every visit, document tobacco status and cessation treatment; also assess occupational, biomass, and other inhalational exposures. Vaccination, physical activity, nutrition, pulmonary rehabilitation, and optimization of cardiovascular and mental-health comorbidity should be integrated with inhaled treatment rather than deferred until advanced disease. Current COPD guidance includes GOLD 2025, ATS pulmonary rehabilitation guidance, and VA/DoD COPD guidance. [10]

Refer appropriate patients to pulmonary rehabilitation for exercise intolerance, activity limitation, post-exacerbation functional loss, or deconditioning. Objective exercise assessment can clarify disproportionate dyspnea and help select patients for rehabilitation. [12][10]

At follow-up, do not use FEV₁ alone as a marker of therapeutic success. Reassess CAT or mMRC, exacerbation frequency and care setting, rescue use, device technique, adverse effects, tobacco exposure, oxygenation when indicated, body weight, and treatment burden. New frequent rescue use or declining rescue response should trigger urgent reassessment for deterioration, alternative diagnoses, and a revised plan. [2][8]
- Obtain sputum culture during frequent exacerbations, severe airflow limitation, or an exacerbation requiring mechanical ventilation. [12]
- Evaluate for obstructive sleep apnea when nocturnal hypoxemia, hypercapnia, or clinical features suggest overlap syndrome; COPD with OSA is associated with greater mortality and hospitalization risk. [12]
- Obtain ECG or echocardiography when cardiac disease or pulmonary hypertension is suspected as a contributor to symptoms. [12]

*Follow-up measures that should trigger action. [2][8][12]*

| Measure | Concerning change | Next action |
| --- | --- | --- |
| Rescue bronchodilator use | Increasing need or declining response [2][8] | Evaluate acute deterioration, exacerbation, adherence, device technique, and competing diagnoses; do not simply increase maintenance doses beyond labeling. |
| Weight | Unexplained or clinically significant loss on roflumilast [3] | Evaluate cause and consider discontinuation. |
| ICS safety | New cough, fever, sputum change, or worsening dyspnea [2] | Assess for pneumonia as well as exacerbation. |
| Anticholinergic symptoms | Eye pain/halos, urinary difficulty, or painful urination on tiotropium [5] | Promptly evaluate for narrow-angle glaucoma or urinary retention; reconsider therapy. |

## Common questions

### Is bronchodilator reversibility required to diagnose COPD?

No. COPD is supported by post-bronchodilator FEV₁/FVC <0.70. Total absence of reversibility is neither required nor the typical finding. [12][13]

### How should blood eosinophils influence COPD therapy?

Use eosinophils to estimate the preventive benefit of ICS added to long-acting bronchodilation: little or no benefit is expected below 100 cells/µL and maximal benefit at or above 300 cells/µL. Weigh this against pneumonia risk and the individual exacerbation history. [12][2]

### When is roflumilast appropriate?

Its U.S. label supports 500 mcg orally once daily to reduce exacerbations in severe COPD associated with chronic bronchitis and prior exacerbations. It is not rescue therapy; avoid it in Child-Pugh B/C disease and monitor weight and psychiatric symptoms. [3]

### When should COPD patients undergo CT?

Consider CT for persistent exacerbations, symptoms disproportionate to lung-function impairment, FEV₁ <45% predicted with substantial hyperinflation, or when lung cancer screening criteria are met. [12]

### Can tiotropium, formoterol, fluticasone furoate/vilanterol, or ensifentrine treat an acute COPD episode?

No. These are maintenance therapies. Acute bronchospasm should be treated with an inhaled short-acting beta₂-agonist; escalating maintenance doses for rescue is not supported by the supplied labeling. [2][4][5][8]

## References
1. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204569Orig1s007lbl.pdf
2. [PDF] breo ellipta - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204275s022lbl.pdf
3. 3851308 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022522s006lbl.pdf
4. highlights of prescribing information — www.fda.gov — https://www.fda.gov/media/182289/download
5. These highlights do not include all the information needed to use SPIRIVA RESPIMAT safely and effectively. See full prescribing information for SPIRIVA RESPIMAT. 
      SPIRIVA® RESPIMAT® (tiotropium bromide inhalation spray), for oral inhalation use Initial U.S. Approval: 2004 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b656b14-fcaa-2741-f6f0-e0be48971c02
6. First Generic Drug Approvals — www.fda.gov — https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals
7. Pharmacokinetics in Patients with Impaired Renal Function — www.fda.gov — https://www.fda.gov/media/78573/download
8. DailyMed - PERFOROMIST- formoterol fumarate dihydrate solution — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af
9. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ ... — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/747949c5-2c91-4909-8a07-71b6826f8e97/spl-doc
10. Chronic obstructive pulmonary disease (COPD) - Guidelines | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/7/guidelines
11. Chronic obstructive pulmonary disease (COPD) - Guidelines | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/7/guidelines
12. Chronic obstructive pulmonary disease (COPD) - Tests | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/7/investigations
13. Chronic obstructive pulmonary disease (COPD) - Criteria | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/7/criteria
14. Chronic Obstructive Pulmonary Disease — jamanetwork.com — https://jamanetwork.com/collections/5563/chronic-obstructive-pulmonary-disease
15. Contemporary Management of Chronic Obstructive ... — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/197584
16. Review of Drug Development Guidance to Treat Chronic ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1540
17. Guideline based knowledge and practice of physicians in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/crj.13468
18. Derivation and validation of a pre-bronchodilator FEV1/ ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666606526001549
19. Causes of misdiagnosis of chronic obstructive pulmonary disease: A systematic scoping review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0954611117301579
20. Prevalence and diagnosis of chronic obstructive pulmonary ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0954611112004660
21. Twenty years of changes in the definition of early chronic obstructive pulmonary disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2772558823000117
22. Chronic Obstructive Pulmonary Disease Diagnosis and ... — agsjournals.onlinelibrary.wiley.com — https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2010.02875.x
23. Clinical guideline highlights for the hospitalist: GOLD COPD ... — shmpublications.onlinelibrary.wiley.com — https://shmpublications.onlinelibrary.wiley.com/doi/10.1002/jhm.13416?af=R
24. Management of chronic obstructive pulmonary disease — academic.oup.com — https://academic.oup.com/ajhp/article/77/4/259/5700876

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.